Liver Fibrosis in Rheumatoid Arthritis Patients Treated with Methotrexate

被引:5
|
作者
Hilal, Ghizlane [1 ]
Akasbi, Nessrine [1 ]
Boudouaya, Hanae [2 ]
Salma, Ksir [1 ]
Harzy, Taoufik [1 ]
机构
[1] CHU Hassan II, Dept Rheumatol, Fes, Morocco
[2] CHU Hassan II, Dept Epidemiol, Fes, Morocco
关键词
Methotrexate; rheumatoid arthritis; hepatic fibrosis; liver fibrosis; anti-TNF therapy; DMARDs; LOW-DOSE METHOTREXATE; THERAPY; HEPATOTOXICITY; EFFICACY;
D O I
10.2174/1573397116666200319155247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Methotrexate (MTX) is a highly effective therapy for patients with rheumatoid arthritis (RA). However, it has been associated with a range of liver related adverse events. The aim of our study was to evaluate the prevalence rate of liver fibrosis in RA patients and to assess the correlation of cumulative MTX dose with hepatic fibrosis in our context. Materials and Methods: This is a cross-sectional study, whose goal is to describe and analyze the factors correlated with the liver fibrosis in RA patients treated with methotrexate especially the cumulative dose of MTX, along the period lying between January 2012 and March 2019. The study was carried out in the Rheumatology Department of the University Hospital Hassan II of Fez. The patients have met the assessment of the ACR 2010 criteria. The data was recorded and analyzed using SPSS v20 univariate and bivariate analysis. A value of p <0.05 has been used to identify factors associated with liver fibrosis. Results: A total of 319 patients with RA were recruited who were on MTX treatment. There were 276 female and 43 male patients (female: male ratio of 6.3). The average age was 53 years + /-12.4 years. The average duration of symptoms was 10.68 +/-6.9 years. RA was seropositive for the rheumatoid factor or the anti-ccp in 90.3 %. Six patients (2%) had developed liver fibrosis while on MTX therapy. In the bivariate analysis, the liver fibrosis is significantly related to the hepatic cytolysis (p<0.001) and to the combination of MTX with other DMARDs (p<0.05). However, the multiple logistic regression analysis did not find any significant association between the groups. Conclusion: In our context, the prevalence rate of hepatic fibrosis in patients with rheumatoid arthritis under methotrexate is low. It is seen much more in patients treated with methotrexate in combination with other disease-modifying anti-rheumatic drugs (DMARDs). These results require confirmation in a larger number of patients.
引用
收藏
页码:293 / 297
页数:5
相关论文
共 50 条
  • [21] Homocysteine level in patients with rheumatoid arthritis treated with methotrexate
    Stanislavchuk, Mykola A.
    Galyutina, Olena Y.
    RHEUMATOLOGY, 2008, 47 : II102 - II102
  • [22] GYNECOMASTIA IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH METHOTREXATE
    THOMAS, E
    LEROUX, JL
    BLOTMAN, F
    JOURNAL OF RHEUMATOLOGY, 1994, 21 (09) : 1777 - 1778
  • [23] Liver steatosis in patients with rheumatoid arthritis treated with methotrexate is associated with body mass index
    Castiella, Agustin
    Lopez-Dominguez, Luis
    Sanchez-Iturri, Maria J.
    Urreta, Iratxe
    De Diego, Andrea
    Belzunegui, Joaquin
    Zapata, Eva
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (05) : 699 - 706
  • [24] Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids
    Yilmaz, L
    Özoran, K
    Gündüz, OH
    Uçan, H
    Yücel, M
    RHEUMATOLOGY INTERNATIONAL, 2001, 20 (02) : 65 - 69
  • [25] Purine enzymes in patients with rheumatoid arthritis treated with methotrexate
    van Ede, AE
    Laan, RFJM
    De Abreu, RA
    Stegeman, ABJ
    van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (12) : 1060 - 1064
  • [26] Liver steatosis in patients with rheumatoid arthritis treated with methotrexate is associated with body mass index
    Agustin Castiella
    Luis Lopez-Dominguez
    Maria J Sanchez-Iturri
    Iratxe Urreta
    Andrea De Diego
    Joaquin Belzunegui
    Eva Zapata
    World Journal of Hepatology, 2023, (05) : 699 - 706
  • [27] Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate
    Miyata, Masayuki
    Kuroda, Masahito
    Unakami, Masamitsu
    Tasaki, Kazuhiro
    Migita, Kiyoshi
    Ohira, Hiromasa
    MODERN RHEUMATOLOGY, 2019, 29 (06) : 936 - 942
  • [28] Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide
    Curtis, J. R.
    Beukelman, T.
    Onofrei, A.
    Cassell, S.
    Greenberg, J. D.
    Kavanaugh, A.
    Reed, G.
    Strand, V.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 43 - 47
  • [29] Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis
    Kim, Tae Yeob
    Kim, Ji Yeoun
    Sohn, Joo Hyun
    Lee, Hye-Soon
    Bang, So-Young
    Kim, Yongsoo
    Kim, Min Yeong
    Jeong, Woo Kyoung
    JOURNAL OF ULTRASOUND IN MEDICINE, 2015, 34 (09) : 1621 - 1630
  • [30] Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis
    Prashant Bafna
    Rasmi Ranjan Sahoo
    Kasturi Hazarika
    Manesh Manoj
    Sumit Rungta
    Anupam Wakhlu
    Clinical Rheumatology, 2021, 40 : 3605 - 3613